Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function
W. Wuyts (Leuven, Belgium), A. Azuma (Tokyo, Japan), J. Distler (Erlangen, Germany), K. Sondergaard (Aarhus, Denmark), S. Proudman (Adelaide, Australia), V. Cottin (Lyon, France), E. Erhardt (Sulzbach, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), M. Alves (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom)
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Wuyts (Leuven, Belgium), A. Azuma (Tokyo, Japan), J. Distler (Erlangen, Germany), K. Sondergaard (Aarhus, Denmark), S. Proudman (Adelaide, Australia), V. Cottin (Lyon, France), E. Erhardt (Sulzbach, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), M. Alves (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom). Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function. 3393
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: